It has also been demonstrated that AR mutations can be found in up to 30% of CRPC patients under ADT; interestingly, the treatment with new antiandrogens could enhance their incidence favouring the clonal selection of tumour cells through the suppression of AR signalling, also increasing AR somatic mutations and the consequent abnormal transcription [111]. This evidence concerns the gene AR and neoplasm.